Inoviq Ltd (AU:IIQ)
ASX:IIQ
Top Page
Inoviq Ltd
(Sydney:IIQ)
Select Model
Select Model
Rating:38Underperform
Price Target:
AU$0.36
▼(-9.50% Downside)
Action:DowngradedDate:10/22/25
Inoviq Ltd's overall stock score is significantly impacted by its poor financial performance, characterized by declining revenues and profitability issues. Technical analysis indicates a bearish trend with oversold conditions, while valuation metrics highlight the lack of profitability and dividend yield. These factors collectively result in a low stock score, suggesting caution for potential investors.
Positive Factors
Low Leverage / Balance Sheet Stability
A very low debt-to-equity ratio (0.0225) gives Inoviq durable financial flexibility to fund R&D or operate through loss-making periods without heavy interest burdens. Lower leverage reduces insolvency risk and preserves optionality for strategic investments over months.
Negative Factors
Declining Revenue and Negative Margins
Material revenue decline and persistently negative gross and operating margins indicate the core business is not scaling profitably. Over 2–6 months this undermines funding for clinical programs, limits commercialization capacity and stresses the need for strategic turnaround or new revenue streams.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage / Balance Sheet Stability
A very low debt-to-equity ratio (0.0225) gives Inoviq durable financial flexibility to fund R&D or operate through loss-making periods without heavy interest burdens. Lower leverage reduces insolvency risk and preserves optionality for strategic investments over months.
Read all positive factors
Inoviq Ltd (IIQ) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$48.57M
Dividend YieldN/A
Average Volume (3M)196.06K
Price to Earnings (P/E)―
Beta (1Y)0.55
Revenue Growth2.33%
EPS Growth12.50%
CountryAU
Employees15
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)N/A
Shares Outstanding140,775,450
10 Day Avg. Volume262,451
30 Day Avg. Volume196,057
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)2.46
Price to Sales (P/S)22.67
P/FCF Ratio-8.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Inoviq Ltd Business Overview & Revenue Model
Company Description
INOVIQ Ltd engages in the research, development, and commercialization of diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. The company offers hTERT test, ...
How the Company Makes Money
Inoviq generates revenue through the commercialization of its diagnostic products and services. The primary revenue streams include sales from its proprietary tests and assays, which are utilized in clinical laboratories and healthcare settings. A...
Inoviq Ltd Financial Statement Overview
Summary
Income Statement
25
Negative
Balance Sheet
45
Neutral
Cash Flow
30
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.22M | 1.82M | 535.12K | 398.19K | 276.75K | 1.27M |
| Gross Profit | -583.05K | -1.56M | 454.11K | -1.04M | -1.88M | -2.21M |
| EBITDA | -7.87M | -6.16M | -6.34M | -9.32M | -19.39M | -6.05M |
| Net Income | -7.24M | -6.93M | -6.55M | -8.97M | -18.20M | -11.15M |
Balance Sheet | ||||||
| Total Assets | 24.52M | 18.46M | 21.71M | 21.51M | 30.78M | 33.52M |
| Cash, Cash Equivalents and Short-Term Investments | 13.80M | 6.52M | 9.23M | 7.81M | 15.39M | 5.00M |
| Total Debt | 270.31K | 376.19K | 776.54K | 730.71K | 998.69K | 1.26M |
| Total Liabilities | 2.26M | 1.74M | 1.72M | 1.89M | 2.49M | 4.46M |
| Stockholders Equity | 22.26M | 16.71M | 19.99M | 19.62M | 28.29M | 29.06M |
Cash Flow | ||||||
| Free Cash Flow | -5.08M | -4.77M | -4.50M | -7.32M | -6.47M | -6.05M |
| Operating Cash Flow | -4.99M | -4.66M | -4.32M | -7.02M | -6.06M | -5.26M |
| Investing Cash Flow | -88.12K | -104.00K | -174.34K | -292.27K | -411.90K | 2.64M |
| Financing Cash Flow | 9.41M | 2.05M | 5.91M | -267.98K | 16.87M | 286.48K |
Inoviq Ltd Technical Analysis
Positive
0.40
Price Trends
0.34
Negative
0.35
Negative
0.37
Negative
Market Momentum
>-0.01
Negative
50.26
Neutral
39.05
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IIQ, the sentiment is Positive. The current price of 0.4 is above the 20-day moving average (MA) of 0.34, above the 50-day MA of 0.34, and above the 200-day MA of 0.37, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 50.26 is Neutral, neither overbought nor oversold. The STOCH value of 39.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:IIQ.
Inoviq Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$65.59M | -4.75 | -476.27% | ― | ― | 56.42% | |
46 Neutral | AU$168.57M | -7.39 | -164.12% | ― | 12.96% | 40.81% | |
42 Neutral | AU$36.50M | -2.45 | -164.22% | ― | ― | 23.85% | |
41 Neutral | AU$18.17M | -2.23 | -23.93% | ― | 62.81% | 16.37% | |
38 Underperform | AU$48.57M | -3.02 | -37.14% | ― | 2.33% | 12.50% |
* Healthcare Sector Average
AU:IIQ
Inoviq Ltd
0.35
-0.06
-13.75%
AU:BDX
BCAL Diagnostics Limited
0.10
<0.01
10.00%
AU:RHY
Rhythm Biosciences Ltd.
0.19
0.12
160.27%
AU:LDX
Lumos Diagnostics Holdings Ltd.
0.21
0.19
950.00%
AU:GSS
Genetic Signatures Ltd.
0.08
-0.36
-81.82%
Inoviq Ltd Corporate Events
Inoviq Director Max Johnston Increases Indirect Shareholding via On-Market Purchase
Apr 1, 2026
Inoviq director Max Johnston has increased his indirect shareholding in the company through Jondol Pty Ltd, the Jondol Super Fund account, by purchasing 100,000 ordinary fully paid shares on market at $0.33 per share on 1 April 2026. Following thi...
INOVIQ Director Mary Harney Buys 60,000 Shares on Market
Mar 29, 2026
INOVIQ director Mary Harney has increased her direct equity stake in the company, purchasing 60,000 ordinary fully paid shares on market over 26–27 March 2026. The transaction, executed at prices of $0.335 and $0.345 per share, lifts her hol...
Inoviq director increases indirect shareholding through on-market purchase
Mar 2, 2026
Inoviq Limited has disclosed a change in director Peter Gunzburg’s indirect shareholding following an on-market purchase. Gunzburg acquired 50,000 ordinary shares at $0.33 per share on 2 March 2026 through associated entities, lifting his to...
Inoviq director Peter Gunzburg lifts indirect shareholding via on-market purchase
Feb 22, 2026
Inoviq has disclosed a change in the indirect interests of director Peter Gunzburg, who has increased his stake in the company through associated entities. On 19 February 2026, Gunzburg acquired 100,000 ordinary shares on-market at $0.33 each, lif...
Inoviq Accelerates Exosome Diagnostics and Therapies After Capital Raise and Positive TNBC Data
Jan 28, 2026
In its December quarterly update, Inoviq reported continued commercial uptake of its EXO-NET exosome capture technology, with 76 customers by year-end and growing demand from pharma, biotech and clinical users despite broader funding uncertainty i...
Inoviq Issues 700,000 Unquoted Options Under Employee Incentive Scheme
Jan 16, 2026
Inoviq Ltd has notified the market of the issue of 700,000 unquoted options under its employee incentive scheme, recorded as Appendix 3G with the ASX. The options, which have various expiry dates and exercise prices and are not intended to be quot...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.